

Ming Yi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/116603/publications.pdf>

Version: 2024-02-01

51
papers

5,511
citations

159358

30
h-index

174990

52
g-index

52
all docs

52
docs citations

52
times ranked

7185
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. <i>Molecular Cancer</i> , 2019, 18, 155.	7.9	723
2	Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. <i>Molecular Cancer</i> , 2018, 17, 129.	7.9	536
3	Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. <i>Molecular Cancer</i> , 2022, 21, 28.	7.9	393
4	Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. <i>Molecular Cancer</i> , 2019, 18, 60.	7.9	361
5	MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. <i>Journal of Clinical Investigation</i> , 2014, 124, 398-412.	3.9	348
6	Regulation of PD-L1 expression in the tumor microenvironment. <i>Journal of Hematology and Oncology</i> , 2021, 14, 10.	6.9	281
7	Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2019, 12, 35.	6.9	220
8	Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. <i>Journal of Hematology and Oncology</i> , 2019, 12, 27.	6.9	211
9	Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. <i>Molecular Cancer</i> , 2019, 18, 125.	7.9	201
10	Organoid technology and applications in cancer research. <i>Journal of Hematology and Oncology</i> , 2018, 11, 116.	6.9	196
11	The role of cancer-derived microRNAs in cancer immune escape. <i>Journal of Hematology and Oncology</i> , 2020, 13, 25.	6.9	145
12	Gut microbiome modulates efficacy of immune checkpoint inhibitors. <i>Journal of Hematology and Oncology</i> , 2018, 11, 47.	6.9	138
13	The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. <i>Journal of Hematology and Oncology</i> , 2020, 13, 72.	6.9	123
14	The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF- β 2 and PD-L1. <i>Journal of Hematology and Oncology</i> , 2021, 14, 27.	6.9	118
15	The role of neoantigen in immune checkpoint blockade therapy. <i>Experimental Hematology and Oncology</i> , 2018, 7, 28.	2.0	99
16	Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1705-1719.	2.0	96
17	<p>Blocking TGF- β 2 Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 9527-9538.	1.0	93
18	Prospects for combining immune checkpoint blockade with PARP inhibition. <i>Journal of Hematology and Oncology</i> , 2019, 12, 98.	6.9	92

#	ARTICLE	IF	CITATIONS
19	The role of exosomes in liquid biopsy for cancer diagnosis and prognosis prediction. <i>International Journal of Cancer</i> , 2021, 148, 2640-2651.	2.3	90
20	Advances and perspectives of PARP inhibitors. <i>Experimental Hematology and Oncology</i> , 2019, 8, 29.	2.0	81
21	Combine and conquer: manganese synergizing anti-TGF- β 2/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers. <i>Journal of Hematology and Oncology</i> , 2021, 14, 146.	6.9	68
22	Epidemiological trends of women's cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study. <i>Biomarker Research</i> , 2021, 9, 55.	2.8	67
23	Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC. <i>Experimental Hematology and Oncology</i> , 2021, 10, 18.	2.0	64
24	The application of histone deacetylases inhibitors in glioblastoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 138.	3.5	59
25	The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis. <i>Experimental Hematology and Oncology</i> , 2019, 8, 26.	2.0	58
26	Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies. <i>Experimental Hematology and Oncology</i> , 2021, 10, 60.	2.0	53
27	MiRNA-mediated EMT and CSCs in cancer chemoresistance. <i>Experimental Hematology and Oncology</i> , 2021, 10, 12.	2.0	47
28	The roles of exosomes in cancer drug resistance and its therapeutic application. <i>Clinical and Translational Medicine</i> , 2020, 10, e257.	1.7	47
29	Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 827921.	2.2	43
30	Recent advances and challenges of bispecific antibodies in solid tumors. <i>Experimental Hematology and Oncology</i> , 2021, 10, 56.	2.0	42
31	Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541987635.	0.8	38
32	Roles of Microvesicles in Tumor Progression and Clinical Applications. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 7071-7090.	3.3	30
33	Prognostic Values of TIM-3 Expression in Patients With Solid Tumors: A Meta-Analysis and Database Evaluation. <i>Frontiers in Oncology</i> , 2020, 10, 1288.	1.3	29
34	CXCL1 as an Unfavorable Prognosis Factor Negatively Regulated by DACH1 in Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1515.	1.3	29
35	Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells. <i>Theranostics</i> , 2022, 12, 747-766.	4.6	28
36	Global burden and trend of acute lymphoblastic leukemia from 1990 to 2017. <i>Aging</i> , 2020, 12, 22869-22891.	1.4	27

#	ARTICLE	IF	CITATIONS
37	Identifying Tumorigenesis and Prognosis-Related Genes of Lung Adenocarcinoma: Based on Weighted Gene Coexpression Network Analysis. <i>BioMed Research International</i> , 2020, 2020, 1-15.	0.9	26
38	The global, regional, and national burden of kidney cancer and attributable risk factor analysis from 1990 to 2017. <i>Experimental Hematology and Oncology</i> , 2020, 9, 27.	2.0	25
39	Distinct Roles of VEGFA and ANGPT2 in Lung Adenocarcinoma and Squamous Cell Carcinoma. <i>Journal of Cancer</i> , 2020, 11, 153-167.	1.2	24
40	Advances of Targeted Therapy for Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 719896.	1.3	23
41	The regulation of cytokine signaling by retinal determination gene network pathway in cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6479-6487.	1.0	17
42	EYA2 Correlates With Clinico-Pathological Features of Breast Cancer, Promotes Tumor Proliferation, and Predicts Poor Survival. <i>Frontiers in Oncology</i> , 2019, 9, 26.	1.3	17
43	CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1295-1308.	1.9	17
44	The role of gut microbiota in immune checkpoint inhibitor therapy. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 481-483.	0.7	16
45	Progression and prognostic value of ECT2 in non-small-cell lung cancer and its correlation with PCNA. <i>Cancer Management and Research</i> , 2018, Volume 10, 4039-4050.	0.9	12
46	RDGN-based predictive model for the prognosis of breast cancer. <i>Experimental Hematology and Oncology</i> , 2020, 9, 13.	2.0	12
47	Prognostic significance of KRT19 in Lung Squamous Cancer. <i>Journal of Cancer</i> , 2021, 12, 1240-1248.	1.2	12
48	Immune pressures drive the promoter hypermethylation of neoantigen genes. <i>Experimental Hematology and Oncology</i> , 2019, 8, 32.	2.0	11
49	Upregulation of STAT1-CCL5 axis is a biomarker of colon cancer and promotes the proliferation of colon cancer cells. <i>Annals of Translational Medicine</i> , 2020, 8, 951-951.	0.7	11
50	The biology of combination immunotherapy in recurrent metastatic head and neck cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2021, 136, 106002.	1.2	6
51	Propofol target-controlled infusion modeling in rabbits: Pharmacokinetic and pharmacodynamic analysis. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2016, 36, 428-433.	1.0	3